Ordaos
NEW YORK, New York, United States · Artificial Intelligence, Biotechnology, Health Care · 32 employees
Ordaōs is a human-enabled, machine-driven drug design company. Our miniPRO™ proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods.
Funding history
- Series seed — $338K — Apr 2025
- Series seed — $3.1M — Sep 2024
- Series seed — $500K — Dec 2023
- Series seed — $332K — Dec 2023
- Series seed — $5.0M — Aug 2022
Recent signals
- Apr 01, 2025: Raised $338K in Series seed
- Sep 11, 2024: Raised $3.1M in Series seed
- Mar 11, 2024: Acquired Ordaōs completes acquisition of the Carterra®LSA® Platform to optimize its machine-driven drug design system
- Dec 29, 2023: Raised $500K in Series seed
- Dec 28, 2023: Raised $332K in Series seed
- Aug 25, 2022: Raised $5.0M in Series seed
- Jun 15, 2022: Raised $10.7M
See plans & pricing → Track Ordaos’s funding, hiring, and signals — with verified contacts — on Fundz.